Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
Launched by SKINGENIX, INC. · Feb 15, 2011
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called MW-III for patients with thermal burns. The goal is to see if MW-III can help these burns heal faster compared to a standard treatment called Silvadene® Cream, which is commonly used for burns. The focus is on how quickly the skin can heal, specifically looking for at least 95% of the burn area to be healed.
To participate in this study, you need to be an adult aged 18 or older with certain types of burns. Specifically, you should have partial thickness burns that cover a small area of your body and are not infected or at high risk for complications. If you join the study, you will be closely monitored as you receive either MW-III or Silvadene® Cream, and your healing progress will be tracked. This trial is open to all genders and is currently recruiting participants, so if you or a loved one are interested, it could be a way to access new treatment options while contributing to important research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adults, 18 years of age or older on the day of signing the informed consent.
- • 2. Thermal Burns not exceeding a total body surface area (TBSA) OF 25%, with at least one partial thickness burn of 0.5% TBSA or greater. If full thickness burn(s) are present at screening, the total full thickness burn area shall not exceed 10% TBSA. Note: TBSA excludes areas of superficial (first degree) burns.
- • 3. Able and willing to give informed consent and comply with study procedures.
- Exclusion Criteria:
- 1. Any burn that at screening is:
- • 1. infected.
- • 2. circumferential or deemed, in the judgment of the investigator, at high risk for developing compartment syndrome.
- • 3. partial thickness that is likely, in the judgment of the Investigator, to require grafting within 72 hours, or other non-protocol intervention.
- • 2. Severe inhalation injury or other significant non-burn trauma.
About Skingenix, Inc.
Skingenix, Inc. is a pioneering biotechnology company focused on developing innovative therapeutic solutions for skin-related conditions. With a commitment to advancing dermatological care, Skingenix harnesses cutting-edge research and technology to create novel treatments aimed at improving patient outcomes. The company collaborates with leading experts in the field and engages in rigorous clinical trials to ensure the safety and efficacy of its products. Through its dedication to scientific excellence and patient-centered approaches, Skingenix is poised to make significant contributions to the dermatology landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Washington, District Of Columbia, United States
Iowa City, Iowa, United States
New Orleans, Louisiana, United States
Phoenix, Arizona, United States
Augusta, Georgia, United States
Sacramento, California, United States
Patients applied
Trial Officials
Kevin Foster
Principal Investigator
Valleywise Health Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials